A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma

OBJECTIVES: Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted therapy, also was assessed in a single-arm trial (ERIVANCE). We e...

Descripción completa

Detalles Bibliográficos
Autores principales: Odom, Dawn, Mladsi, Deirdre, Purser, Molly, Kaye, James A., Palaka, Eirini, Charter, Alina, Jensen, Jo Annah, Sellami, Dalila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457749/
https://www.ncbi.nlm.nih.gov/pubmed/28607774
http://dx.doi.org/10.1155/2017/6121760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457749/
https://www.ncbi.nlm.nih.gov/pubmed/28607774
http://dx.doi.org/10.1155/2017/6121760

Ejemplares similares